JPRN-jRCTs051200075已完成2 期
Evaluation study of usefulness of cancer specific PET probe F18-NKO-035 for lung cancer
Watabe Tadashi0 个研究点目标入组 9 人开始时间: 2020年10月27日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 9
研究概览
简要总结
A novel PET probe F-18 NKO-035 PET examination targeting LAT1 (L-type amino acid transporter 1) was performed in lung cancer patients (n=9) and compared with immunostaining. The accumulation of F18-NKO-035 PET in lung cancer was low, and the correlation with the intensity of LAT1 expression in immunostaining was not clear. FDG-PET showed markedly high accumulation in lung cancers with high LAT1 expression. F18-NKO-035 should be further improved as a LAT1 probe.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1) Persons over 20 years old who have been diagnosed with lung cancer with a high probability by pathological diagnosis or CT examination
- •2) Those who have a solid lesion with a maximum diameter of 2 cm or more in the lung in the CT examination
- •3) The surgery is planned as above, and pathological evaluation of the lesion can be performed.
- •4) Persons who have given their written consent to participate in this research
排除标准
- •1) Persons whose general condition is extremely poor
- •2) Pregnant women and breast-feeding subjects or those who wish to become pregnant
- •3) Persons who need to use sedatives for PET/CT imaging
- •4) Persons who are judged to be unsuitable for the research by the investigator
研究者
相似试验
已完成
1 期
Safety evaluation of PET probe F18-NKO-035ormal healthy volunteerLAT1 PET diagnosisJPRN-jRCTs051190057Watabe Tadashi4
已完成
早期 1 期
[18F]-F13640 as a New Brain RadiopharmaceuticalNeurological PathologyHealthy SubjectsNCT03347331Hospices Civils de Lyon20
已完成
1 期
F-18 TFB-PET Studies in Cancer Patients Undergoing NIS-containing Viral TherapiesMyeloma Before MV-NIS TreatmentEndometrial Cancer Before VSV-hINF-NIS TreatmentNCT03456908Mayo Clinic2
终止
不适用
FLT-PET Imaging for MDSMDSAMLNCT01535456University of Wisconsin, Madison1
已完成
1 期
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis TherapyAdult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaMetastatic Squamous Neck Cancer With Occult Primary Squamous Cell CarcinomaRecurrent Adenoid Cystic Carcinoma of the Oral CavityRecurrent Adult Brain TumorRecurrent Basal Cell Carcinoma of the LipRecurrent Colon CancerRecurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal CavityRecurrent Hypopharyngeal CancerRecurrent Inverted Papilloma of the Paranasal Sinus and Nasal CavityRecurrent Laryngeal CancerRecurrent Lip and Oral Cavity CancerRecurrent Lymphoepithelioma of the NasopharynxRecurrent Lymphoepithelioma of the OropharynxRecurrent Metastatic Squamous Neck Cancer With Occult PrimaryRecurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal CavityRecurrent Mucoepidermoid Carcinoma of the Oral CavityRecurrent Nasopharyngeal CancerRecurrent Non-small Cell Lung CancerRecurrent Oropharyngeal CancerRecurrent Pancreatic CancerRecurrent Paranasal Sinus and Nasal Cavity CancerRecurrent Rectal CancerRecurrent Renal Cell CancerRecurrent Salivary Gland CancerStage IIIA Breast CancerStage IIIA Non-small Cell Lung CancerStage IIIB Breast CancerStage IIIB Non-small Cell Lung CancerStage IIIC Breast CancerStage IV Breast CancerStage IV Non-small Cell Lung CancerStage IV Pancreatic CancerStage IV Renal Cell CancerMale Breast CancerStage IVA Colon CancerStage IVA Rectal CancerStage IVA Salivary Gland CancerStage IVB Colon CancerStage IVB Salivary Gland CancerStage IVC Salivary Gland CancerUnspecified Adult Solid Tumor, Protocol SpecificTongue CancerNCT01806675Sanjiv Sam Gambhir25